Intratympanic therapy in XXXX or disease: up to date evidence for clinical practice.

@entity1 @entity801 @entity9303 @entity392 @entity9905 @entity74 @entity230 @entity4540 @entity393 @entity15
BACKGROUND: @entity9303 or disease ( @entity15 /D) is typically characterised by episodic vertigo, @entity9905 , @entity392 and fluctuating @entity393 . There are multiple options available for treatment with variation in consensus on the best intervention. OBJECTIVE: To evaluate the evidence on the efficacy of intratympanic therapies [ @entity230 , @entity801 , antivirals and other therapies] on the frequency and severity of vertigo and other symptoms of @entity15 /D. SEARCH STRATEGY: A literature search was performed on AMED, EMBASE, HMIC, MEDLINE, PsycINFO, BNI, CINAHL, HEALTH BUSINESS ELITE, CENTRAL and Cochrane Ear, Nose and @entity74 group trials register using various MeSH. The search was restricted to English and @entity1 subjects, and the last date of search was December 2014. SELECTION CRITERIA: Randomised controlled trials of intratympanic therapies [ @entity230 , @entity801 antivirals and latanoprost] versus a placebo or another treatment. RESULTS: We analysed 8 RCT's comparing intratympanic @entity230 , @entity801 , @entity4540 (antiviral) and latanoprost versus another form of intratympanic treatment or placebo. CONCLUSIONS: On the basis of 6 RCT's (n = 242), there is evidence to support the effectiveness of intratympanic @entity230 and @entity801 to control symptoms of vertigo in @entity15 /D albeit with a risk of @entity393 with @entity801 . However, there was no consensus found on doses or treatment protocols. There was no evidence to support the use of other forms of intratympanic therapy (antivirals and latanoprost) in @entity15 /D.
